Latest 30 News in the Life Sciences Industry
PR Newswire Association LLC.
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
07 Jun 2026
GlobeNewswire
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
07 Jun 2026
GlobeNewswire
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
07 Jun 2026
GlobeNewswire
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
07 Jun 2026
PR Newswire Association LLC.
Sectra's year-end report 2025/2026: Long-term investments drive growth and profit
05 Jun 2026
GlobeNewswire
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
05 Jun 2026
GlobeNewswire
New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity
05 Jun 2026
PR Newswire Association LLC.
Micro Imaging Technology is pleased to Announce the Acquisition of Cellmyx
05 Jun 2026
PR Newswire Association LLC.
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
04 Jun 2026
GlobeNewswire
ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
04 Jun 2026
PR Newswire Association LLC.
Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
04 Jun 2026
PR Newswire Association LLC.
Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer's
04 Jun 2026
GlobeNewswire
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
04 Jun 2026
PR Newswire Association LLC.
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
04 Jun 2026
PR Newswire Association LLC.
Essity recognized on CDP Supplier Engagement A List for seventh consecutive year
03 Jun 2026
PR Newswire Association LLC.
Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments
03 Jun 2026
GlobeNewswire
Coloplast’s Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of men
03 Jun 2026
GlobeNewswire
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
03 Jun 2026
GlobeNewswire
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
03 Jun 2026
PR Newswire Association LLC.
Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting
02 Jun 2026
GlobeNewswire
Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference
02 Jun 2026
PR Newswire Association LLC.
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
02 Jun 2026
GlobeNewswire
Evosep and Molecular You Announce Strategic Collaboration to Scale Standardized Multi-Omic Testing Globally
02 Jun 2026
GlobeNewswire
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
01 Jun 2026
PR Newswire Association LLC.
The Board of Directors of Bioretec Ltd resolved on a new stock option plan
01 Jun 2026
GlobeNewswire
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
01 Jun 2026
PR Newswire Association LLC.
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
06 Jun 2026
Latest News All News
Upcoming Events All Events
- June 2026
- San Diego: RESI San Diego 2026
- San Diego: BIO 2026
- July 2026
- Taipei: BIO Asia-Taiwan